Drug Trial Radar · NCT05998941
A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer
Last checked: Nov 20, 2026Latest source record: Nov 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Aug 2023
Primary completion
Feb 2025
Study completion Jun 2025
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study used a single-arm, open phase II multicenter trial design. All eligible subjects received TQB2868 plus platinum-based chemotherapy with or without bevacizumab. A total of 39 subjects will be enrolled.
Conditions
- Cervical Cancer
Interventions
TQB2868 injectionDrug
TQB2868 injection is an anti-programmed cell death protein 1 (PD-1)/ transforming growth factor-β (TGF-β) dual-function fusion protein.
Paclitaxel injectionDrug
Paclitaxel injection prevents depolymerization of microtubules, inhibits mitosis, and hinders normal cell division.
Cisplatin injectionDrug
Cisplatin injection can inhibit the DNA replication process of cancer cells
Carboplatin injectionDrug
Carboplatin injection acts directly on DNA, thus inhibiting the vigorous division of tumor cells.
Bevacizumab injectionDrug
Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Investigator-assessed objective response rate (ORR)Time frame: Baseline to CR or PR ,about 12 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.